Sironax Granted Patent for RIP1 Kinase Inhibitors
Summary
USPTO granted patent US12612388B2 to Sironax Ltd. on April 28, 2026, covering receptor-interacting protein 1 (RIP1) kinase inhibitors including piperazine heterocyclic amide urea compounds, along with corresponding sulfonamides and stereoisomers. The patent also protects related pharmaceutical compositions and methods of treatment for conditions addressable by RIP1 inhibition. The filing date was May 20, 2021, with 25 claims allowed across three CPC classifications.
“The present disclosure provides compounds including piperazine heterocyclic amide urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof.”
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
USPTO issued patent US12612388B2 to Sironax Ltd. for compounds that inhibit human receptor interacting protein 1 kinase (RIP1), including piperazine heterocyclic amide urea compounds, corresponding sulfonamides, and their pharmaceutical salts, hydrates, and stereoisomers.
Parties seeking to develop or commercialize RIP1 kinase inhibitor products incorporating piperazine heterocyclic amide urea chemistry should conduct freedom-to-operate analysis, as Sironax Ltd. now holds enforceable patent rights in this chemical space through 2041 at minimum.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas
Grant US12612388B2 Kind: B2 Apr 28, 2026
Assignee
SIRONAX LTD.
Inventors
Yaning Su, Zhiyuan Zhang, Zhaolan Zhang, Yanping Xu
Abstract
The present disclosure provides compounds including piperazine heterocyclic amide urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
CPC Classifications
C07D 403/12 C07D 401/14 C07D 491/107
Filing Date
2021-05-20
Application No.
17998568
Claims
25
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.